{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:29:58Z","timestamp":1794360598131,"version":"4.9.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hashimoto encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis, has been defined by sub-acute onset encephalopathy, with elevated thyroid antibodies, and immunotherapy responsiveness, in the absence of specific neural autoantibodies. We aimed to retrospectively review 144 cases referred with suspected Hashimoto encephalopathy over a 13-year period, and to determine the clinical utility of thyroid antibodies in the course of evaluation of those patients. One hundred and forty-four patients (all thyroid antibody positive) were included; 72% were women. Median age of symptom onset was 44.5\u2009years (range, 10\u201387). After evaluation of Mayo Clinic, 39 patients (27%) were diagnosed with an autoimmune CNS disorder [autoimmune encephalopathy (36), dementia (2) or epilepsy (1)]. Three of those 39 patients had neural-IgGs detected (high glutamic acid decarboxylase-65, \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-receptor and neural-restricted unclassified antibody), and 36 were seronegative. Diagnoses among the remaining 105 patients (73%) were functional neurological disorder (n\u2009=\u200920), neurodegenerative disorder (n\u2009=\u200918), subjective cognitive complaints (n\u2009=\u200914), chronic pain syndrome (n\u2009=\u200912), primary psychiatric (n\u2009=\u200911), sleep disorder (n\u2009=\u200910), genetic\/developmental (n\u2009=\u20098), non-autoimmune seizure disorders (n\u2009=\u20092) and other (n\u2009=\u200910). More patients with autoimmune CNS disorders presented with sub-acute symptom onset (P\u2009&amp;lt;\u20090.001), seizures (P\u2009=\u20090.008), stroke-like episodes (P\u2009=\u20090.007), aphasia (P\u2009=\u20090.04) and ataxia (P\u2009=\u20090.02), and had a prior autoimmune history (P\u2009=\u20090.04). Abnormal brain MRI (P\u2009=\u20090.003), abnormal EEG (P\u2009=\u20090.007) and CSF inflammatory findings (P\u2009=\u20090.002) were also more frequent in the autoimmune CNS patients. Patients with an alternative diagnosis had more depressive symptoms (P\u2009=\u20090.008), anxiety (P\u2009=\u20090.003) and chronic pain (P\u2009=\u20090.002). Thyoperoxidase antibody titre was not different between the groups (median, 312.7 versus 259.4\u2009IU\/ml; P\u2009=\u20090.44; normal range, &amp;lt;9\u2009IU\/ml). None of the non-autoimmune group and all but three of the CNS autoimmune group (two with insidious dementia presentation, one with seizures only) fulfilled the autoimmune encephalopathy criteria proposed by Graus et al. (A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391\u2013404.) (sensitivity, 92%; specificity, 100%). Among patients who received an immunotherapy trial at our institution and had objective post-treatment evaluations, the 16 responders with autoimmune CNS disorders more frequently had inflammatory CSF, compared to 12 non-responders, all eventually given an alternative diagnosis (P\u2009=\u20090.02). In total, 73% of the patients referred with suspected Hashimoto encephalopathy had an alternative non-immune-mediated diagnosis, and more than half had no evidence of a primary neurological disorder. Thyroid antibody prevalence is high in the general population, and does not support a diagnosis of autoimmune encephalopathy in the absence of objective neurological and CNS-specific immunological abnormalities. Thyroid antibody testing is of little value in the contemporary evaluation and diagnosis of autoimmune encephalopathies.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaa233","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T18:01:49Z","timestamp":1609956109000},"source":"Crossref","is-referenced-by-count":54,"title":["Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-8035","authenticated-orcid":false,"given":"Cristina","family":"Valencia-Sanchez","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Mead-Harvey","sequence":"additional","affiliation":[{"name":"Health Science Research, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max R","family":"Trenerry","sequence":"additional","affiliation":[{"name":"Department of Psychology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L","family":"Zalewski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"2021052614140116400_fcaa233-B1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1-associated cognitive impairment: presentation and long-term outcome","volume":"87","author":"Arino","year":"2016","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B2","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000009987","article-title":"Sleep disorders in anti-NMDAR encephalitis","volume":"95","author":"Ari\u00f1o","year":"2020","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(66)92876-5","article-title":"Hashimoto\u2019s disease and encephalopathy","volume":"288","author":"Brain","year":"1966","journal-title":"Lancet"},{"key":"2021052614140116400_fcaa233-B4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archneur.63.2.197","article-title":"Steroid-responsive encephalopathy associated with autoimmune thyroiditis","volume":"63","author":"Castillo","year":"2006","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/archneur.60.2.164","article-title":"Hashimoto encephalopathy: syndrome or myth?","volume":"60","author":"Chong","year":"2003","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B6","doi-asserted-by":"crossref","first-page":"e1997","DOI":"10.1212\/WNL.0000000000005605","article-title":"Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis","volume":"90","author":"de Bruijn","year":"2018","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","article-title":"Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction","volume":"323","author":"Dubey","year":"2018","journal-title":"J Neuroimmunol"},{"key":"2021052614140116400_fcaa233-B8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00415-006-0170-7","article-title":"The neurological disorder associated with thyroid autoimmunity","volume":"253","author":"Ferracci","year":"2006","journal-title":"J Neurol"},{"key":"2021052614140116400_fcaa233-B9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol"},{"key":"2021052614140116400_fcaa233-B10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4065\/mcp.2010.0326","article-title":"Autoimmune dementia: clinical course and predictors of immunotherapy response","volume":"85","author":"Flanagan","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"2021052614140116400_fcaa233-B11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"2021052614140116400_fcaa233-B12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"},{"key":"2021052614140116400_fcaa233-B13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2021052614140116400_fcaa233-B14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2265.2000.01146.x","article-title":"Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study","volume":"53","author":"Kalmijn","year":"2000","journal-title":"Clin Endocrinol"},{"key":"2021052614140116400_fcaa233-B15","first-page":"278","volume-title":"Clinical examinations in neurology. Mayo Clinic and Mayo Foundation","author":"Klass","year":"1981","edition":"5th edn."},{"key":"2021052614140116400_fcaa233-B16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archneur.1991.00530190071018","article-title":"The short test of mental status. Correlations with standardized psychometric testing","volume":"48","author":"Kokmen","year":"1991","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.autrev.2016.09.008","article-title":"Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): characteristics, treatment and outcome in 251 cases from the literature","volume":"15","author":"Laurent","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2021052614140116400_fcaa233-B18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ane.12556","article-title":"Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT","volume":"134","author":"Litmeier","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"2021052614140116400_fcaa233-B19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/B978-0-323-35387-8.00004-4","volume-title":"The abnormal EEG. Rowan\u2019s primer of EEG","author":"Marcuse","year":"2016","edition":"2nd edn."},{"key":"2021052614140116400_fcaa233-B20","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1212\/WNL.0000000000008785","article-title":"Hashimoto encephalopathy in the 21st century","volume":"94","author":"Mattozzi","year":"2020","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B21","first-page":"538","article-title":"Autoimmune encephalopathies and dementias","volume":"22","author":"McKeon","year":"2016","journal-title":"Continuum"},{"key":"2021052614140116400_fcaa233-B22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/archneurol.2008.556","article-title":"Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images","volume":"66","author":"McKeon","year":"2009","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mus.23774","article-title":"Striational antibodies in a paraneoplastic context","volume":"47","author":"McKeon","year":"2013","journal-title":"Muscle Nerve"},{"key":"2021052614140116400_fcaa233-B24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(19)30405-5","article-title":"Functional cognitive disorders: a systematic review","volume":"7","author":"McWhirter","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2021052614140116400_fcaa233-B25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/practneurol-2019-002494","article-title":"Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2","volume":"20","author":"Michael","year":"2020","journal-title":"Pract Neurol"},{"key":"2021052614140116400_fcaa233-B26","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2021052614140116400_fcaa233-B27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/BF03346432","article-title":"Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders","volume":"31","author":"Nakamura","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2021052614140116400_fcaa233-B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2013.05.009","article-title":"Diagnostic and therapeutic aspects of Hashimoto\u2019s encephalopathy","volume":"331","author":"Olmez","year":"2013","journal-title":"J Neurol Sci"},{"key":"2021052614140116400_fcaa233-B29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1365-2265.1996.d01-1558.x","article-title":"The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests","volume":"45","author":"Oomen","year":"1996","journal-title":"Clin Endocrinol"},{"key":"2021052614140116400_fcaa233-B30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/archneurol.2011.2985","article-title":"Autoimmune epilepsy: clinical characteristics and response to immunotherapy","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1444.018","article-title":"Hashimoto\u2019s encephalopathy","volume":"1142","author":"Schiess","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"2021052614140116400_fcaa233-B32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1001\/archneur.60.12.1812-a","article-title":"The uncertain nosology of Hashimoto encephalopathy","volume":"60","author":"Schott","year":"2003","journal-title":"Arch Neurol"},{"key":"2021052614140116400_fcaa233-B33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/WNL.41.2_Part_1.228","article-title":"Hashimoto\u2019s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers\u2013report of 5 cases","volume":"41","author":"Shaw","year":"1991","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00415-011-6266-8","article-title":"Autoimmunity as a prognostic factor in sporadic adult onset cerebellar ataxia","volume":"259","author":"Sivera","year":"2012","journal-title":"J Neurol"},{"key":"2021052614140116400_fcaa233-B35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"2021052614140116400_fcaa233-B36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0028-3886.76857","article-title":"Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis","volume":"59","author":"Tuzun","year":"2011","journal-title":"Neurol India"},{"key":"2021052614140116400_fcaa233-B37","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0000000000002637","article-title":"The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies","volume":"86","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B38","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology"},{"key":"2021052614140116400_fcaa233-B39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.4065\/73.12.1161","article-title":"Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus","volume":"73","author":"Walikonis","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"2021052614140116400_fcaa233-B40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaa233\/35407029\/fcaa233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/3\/2\/fcaa233\/38247398\/fcaa233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/braincomms\/article-pdf\/3\/2\/fcaa233\/38247398\/fcaa233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T13:40:24Z","timestamp":1622036424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaa233\/6064134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaa233","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,1,5]]},"article-number":"fcaa233"}}